A Randomized Controlled Study of Digitalized Cognitive Behavioral Intervention for Antenatal Depression

February 16, 2024 updated by: Andre Sourander, University of Turku

Randomized Controlled Trial of Digitalized Cognitive Behavioral Therapy With Telephone Coaching for Mothers Suffering From Depression During Pregnancy

The main objective of the current research project is to evaluate the effectiveness of the digitalized cognitive behavioral therapy program including telephone coaching for antenatal depressive symptoms. The participants are screened from the general population of pregnant women, as a part of the routine maternity health care check-ups. Mothers with depressive symptoms will be randomized into intervention group receiving guided digitalized treatment program or control group receiving education material about depression in digital form.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Tiia Ståhlberg
  • Phone Number: 0504381160
  • Email: tthuht@utu.fi

Study Locations

      • Turku, Finland
        • Recruiting
        • University of Turku
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • fluent in written and spoken Finnish or Swedish
  • access to computer or mobile phone with internet
  • between 12 and 22 weeks pregnant
  • screening and baseline score on the EPDS ≥10 points

Exclusion Criteria:

  • lifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression)
  • active suicidal ideation
  • severe substance abuse or dependence
  • actively ongoing psychotherapy
  • participates in another intervention study aiming at treating the symptoms of antenatal depression
  • multiple pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Digitalized CBT intervention with phone coaching
Participants receive weekly sessions of internet-based CBT, including telephone coaching
Digitally delivered CBT intervention with weekly phone coaching
Active Comparator: Psychoeducation about depression
Participants receive psychoeducative material about depression in digitalized form.
Psychoeducational material about depression in a digitalized form

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Edinburgh Postnatal Depression Scale (EPDS)
Time Frame: Baseline and 11 weeks after randomization
EPDS is a ten-item self-report questionnaire originally developed to screen for postpartum depression. The respondents are asked about the symptoms of depression. The total score ranges from 0 to 30.
Baseline and 11 weeks after randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the General Anxiety Disorder 7-item scale (GAD-7)
Time Frame: Baseline and 11 weeks after randomization
To assess the change in anxiety symptoms from baseline to follow-up, we will use the Generalized Anxiety Disorder 7-item Scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006), which is a brief screening measure including seven items asking about anxiety symptoms experienced in the previous two weeks.
Baseline and 11 weeks after randomization
Change in the Beck Depression Inventory II (BDI-II)
Time Frame: Baseline and 11 weeks after randomization
To assess the change in depressive symptoms BDI-II will be used.
Baseline and 11 weeks after randomization
Social Phobia Inventory (SPIN)
Time Frame: Baseline and 11 weeks after randomization
To assess the change in Social Phobia SPIN will be used
Baseline and 11 weeks after randomization
Pregnancy-Related Anxiety Questionnaire-Revised (PRAQ)
Time Frame: Baseline and 11 weeks after randomization
To assess the change in pregnancy related anxiety PRAQ will be used
Baseline and 11 weeks after randomization
Perceived Stress Scale (PSS)
Time Frame: Baseline and 11 weeks after randomization
To assess the change in perceived stress PSS will be used
Baseline and 11 weeks after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andre Sourander, Professor, University of Turku, Research Center for Child Psychiatry

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 10, 2021

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

January 7, 2020

First Submitted That Met QC Criteria

January 7, 2020

First Posted (Actual)

January 10, 2020

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 16, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Digitalized CBT with phone coaching

3
Subscribe